BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• 

  Huntington’s disease

  UniQure eyes UK approval for embattled Huntington’s gene therapy after FDA quarrel

  UniQure plans to submit AMT-130 to the U.K.’s Medicines and Healthcare products Regulatory Agency in the third quarter of 2026 based on Phase 1/2 data showing a 75% slowing of disease—the same data the FDA has deemed unacceptable for a biologics license application.

  April 30, 2026

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Earnings

  Lilly’s weight loss pill reaches brand new patients, even without full-court marketing press

  Foundayo became available on April 9 and has already reached 20,000 patients as Eli Lilly builds its marketing machine for the weight loss pill.

  April 30, 2026

   · 

  3 min read

   · 

  Annalee Armstrong
• 

  Earnings

  Merck drops early-stage TROP ADC, keeps deal doors open as Keytruda clock ticks

  On the heels of several big buys, Merck still has eyes for M&A—particularly in the oncology, immunology and cardiometabolic spaces—as the quest continues for a candidate that can top Keytruda.

  April 30, 2026

   · 

  5 min read

   · 

  Gabrielle Masson
• 

  Company closure

  6 biotechs that called it quits in Q1

  Six biotechs based in California, Massachusetts, Washington and Denmark had to halt drug development efforts this year. One of their CEOs is now in an interim chief executive role at another biotech.

  April 30, 2026

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Opinion

  Tackling drug resistance must become biotech’s next frontier

  We must treat drug resistance as a central scientific priority rather than an unavoidable complication.

  April 30, 2026

   · 

  5 min read

   · 

  John Yu
• 

  Job Trends

  7 companies hiring in North Carolina now

  Looking for a biopharma job in North Carolina? Check out the BioSpace list of seven companies hiring life sciences professionals like you.

  April 30, 2026

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Job Trends

  Show, don’t tell: doing free work during the interview process

  Over one-third of BioSpace LinkedIn poll respondents have done free work while interviewing for jobs. A recruiting expert and career coach discuss why employers make work requests and how biopharma professionals should evaluate and respond to them.

  April 30, 2026

   · 

  6 min read

   · 

  Angela Gabriel
• 

  Weight loss

  Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act

  Amylin drugs have become the next big thing in obesity. Eli Lilly CEO David Ricks, understandably, thinks his rivals don’t have a chance for one key reason.

  April 30, 2026

   · 

  2 min read

   · 

  Annalee Armstrong
• 

  Alzheimer’s disease

  GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints

  Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.

  April 30, 2026

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Pipeline

  AstraZeneca prunes asthma, rare disease pipeline, cultivates cancer portfolio

  While AstraZeneca has discontinued work on four assets—including one in asthma and another in acromegaly—the pharma has also elected to take forward a bispecific antibody that destroys the EGFR protein.

  April 30, 2026

   · 

  2 min read

   · 

  Tristan Manalac